Summary Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy. There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasma oestrone concentrations were higher in non-responders at 1 and 2 months after starting AG (Means: NR 106+50, R 84+26pmoll1-, P<0.05; highest value NR 121+51, R 99+24pmoll1, P<0.05). High oestrone levels were correlated with bulky liver secondaries, but not with age, tumour-free interval, time from last menstrual period, time from relapse to start of AG or body weight. Non-responders had higher mean prolactin levels on treatment (prolactin <SOOmIUl-l in 14/40 NR, 2/35 R, P<0.01). High oestrone or prolactin levels were present in 28/41 NR and 6/40 R (P<0.001). Dehydroepiandrosterone sulphate suppression did not differ between R and NR. The differences in peripheral endocrine environment in non-responding patients suggest that oestrogen metabolism may differ in non-responding patients and that sub-groups could be selected for rational endocrine therapy.
There have been many attempts to correlate peripheral hormone changes with response to endocrine ablative or additive therapy in advanced postmenopausal breast cancer (Atkins et al., 1968; Bates et al., 1976; Bulbrook et al., 1958; Irvine et al., 1961; Juret & Hayem, 1961; McAllister et al., 1960; Swyer et al., 1961) . These studies have used urinary assays or not measured the main oestrogen in postmenopausal plasma, oestrone. They have not shown a correlation with response, apart from a urinary discriminant function which occurs in many conditions and is probably due to stress (Durant & Miller, 1973) . Although oestrogen receptor positivity of the primary or secondary tumour correlates with response to endocrine therapy, only 50% of oestrogen receptor-positive tumours respond (McGuire, 1978; Hawkins et al., 1980) . We have measured peripheral hormones in postmenopausal patients with advanced breast cancer receiving treatment with aminoglutethimide and hydrocortisone (Smith et al., 1978) . This treatment suppresses oestrone (E1), oestradiol (E2) and dehydroepiandrosterone sulphate (DHAS) levels (Santen et al., 1977a therapy and if any particular hormone pattern was associated with failure to respond. In this regard it is interesting to note that Worgul et al. (1982) have shown that peripheral oestrone (E1) and dehydroepiandrosterone levels may rise 1-2 years after adrenalectomy in patients with breast cancer and this may be related to recurrence of the tumour.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone by the 20,22 desmolase complex, an early step in the adrenal synthesis of androgens (Dexter et al., 1967) . Aminoglutethimide is usually combined with a replacement dose of hydrocortisone to prevent a reflex rise of ACTH that may overcome the block (Santen et al., 1977a ).
An additional action of aminoglutethimide is inhibition of the peripheral conversion of androgens to oestrogens by aromatase, the main source of oestrogens in the postmenopausal woman (Santen et al., 1978; Grodin et al., 1973) .
Patients and methods
Eighty-one patients with advanced postmenopausal breast cancer were studied for the effects of aminoglutethimide (AG) on plasma hormones. These patients all had progressing disease and had been entered into a phase II study of AG in advanced breast cancer (Harris et al., 1982) , a randomised study of tamoxifen versus AG (Smith et al., 1981) or a study of incremental dose AG (Harris et al., 1982b 
Response
Response was assessed by standard UICC criteria at 3 months or sooner if disease progressed (Hayward et al., 1977) . There were 41 patients with progressive disease (non-responders, NR) and 40 patients with a response to therapy (responders, R). Thirty patients had a partial response for > 3 months, 2 patients had a complete response and 8 patients had a stable disease for > 6 months.
Blood samples Blood was taken before treatment in 29 nonresponders and 17 responders. Samples were taken at monthly intervals after the start of treatment, -3 h after the morning dose of AG, in all 81 patients. Plasma was stored at -20°C until analysis. Two or more samples were taken from 32 responders, but only 21 non-responders, mainly because of progressive disease at 1 month (10 patients stopped) or 2 months (another 11 stopped).
Hormone assays Steroid hormones were measured by radioimmunoassay (RIA) according to previously described methodologies: testosterone, 170H progesterone, 4A-androstenedione and DHAS (Harris et al., 1982a) ; oestrone and oestradiol (Harris et al., 1982b significantly higher in non-responders ( Figure 2) ; 18/41 non-responders had oestrone >120pmoll-1 (mean value for highest oestrone in nonresponders). The lowest oestrone on treatment was lower in responders, but of borderline significance (P= 0.07).
Patient histories were examined of clinical features that might be associated with levels of oestrone. There was no correlation with age, years since the menopause or tumour-free interval with response (Table II) . The mean body weight in responders was 65.2 kg ± 10.8 (s.d.) and 57.9 kg ± 9.2 (s.d.) in non-responders (P<0.002). The mean body weight in the 18 non-responders with high oestrone was 59.2 kg ± 9.6 (s.d.) and in the other 23 nonresponders it was 56.9 kg ± 9 (s.d.) (P= 0.44) . Similarly, there was no relationship between response and time from first recurrence to the time of starting treatment with AG (Table III) . The nonresponders with high oestrone did not differ from other non-responders, or responders with respect to age, years since menopause, tumour-free interval or time of starting AG.
However, there was a significant association of high oestrogen with bulky liver secondaries (i.e. more than 1/3 of the liver involved on isotope scan, palpable liver, and raised alkaline phosphatase and aspartate transaminase): 6/9 patients with bulky liver secondaries had oestrone levels higher than 120pmoll-1, compared with 16/72 patients without bulky liver secondaries (X2 7.98, P<0.01). If patients with bulky liver secondaries were excluded from analysis, 3/38 responders and 13/34 nonresponders had oestrone greater than 120pmollP1 (X2 9.55, P <0.01). Thus, liver secondaries did not account for the majority of patients with high oestrone.
Oestradiol Oestradiol Jevels were suppressed to a similar extent to oestrone and although percentage suppression was less in non-responders, this was not significant.
Androgens
Dehydroepiandrosterone sulphate (DHAS) The mean levels on treatment were suppressed to similar (Table I) . A4 Androstenedione and 17 OH progesterone The levels of these hormones did not differ between responders and non-responders (Table I ). The range of A4 androstenedione in non-responders was 0.7-7.3 nmoll-1, and 3/4 highest values were in the patients with bulky liver secondaries (7.5, 5.3, 3.3 nmol -1).
Sex-hormone-binding globulin (SHBG) SHBG levels on treatment were not significantly different in responders and non-responders (Table  I) . Because of the effects of tamoxifen on SHBG (Sakai et al., 1978) , the values of SHBG before treatment were assessed separately in those receiving tamoxifen in the previous 2 months (26 patients) and those not receiving tamoxifen in the previous 2 months (17).
Ten of 11 patients with SHBG levels >95nmol DHT bound 1-l had received tamoxifen in the previous 2 We found that the presence of bulky liver metastases is associated with high oestrone levels. Variation in AG metabolism associated with liver secondaries in unlikely to explain the high oestrone levels, since we have found equivalent oestrone suppression with doses of AG of 250mg 2x day, 3x day or 4x day (Harris et al., 1982b) . It is possible that oestrone clearance is impaired by the bulky liver secondaries, which would lead to higher circulating levels of oestrone. In cirrhosis higher A4 androstenedione production and increased aromatisation of A4 androstenedione to oestrone have been observed (Gordon et al., 1975; Kley et al., 1976) . It is interesting that the non-responders with liver secondaries who had A4 androstenedione levels measured had high values. The liver is a site that responds poorly to endocrine therapy, although it is often oestrogen receptor-positive (Maas & Jonat, 1981; King, 1975) . Our observations on oestrone suppression may partly account for this. We are currently carrying out further investigations into the association of liver metastases with high steroid concentrations. Another steroid hormone, medroxyprogesterone acetate, when given to patients with advanced breast cancer, reaches higher plasma levels in those with liver secondaries compared to those without (Milano et al., 1982) .
The liver deposits do not, however, account for the majority of cases with high oestrone levels. Kirscher et al. (1978) found that conversion of androstenedione to oestrone accounts for only 65-75% of total production rate of oestrone in women with breast cancer versus 92-95% in controls. This may explain the observation of Santen et al. (1977a) and our observations that oestrone concentrations are only about 60% suppressed, although AG inhibits aromatisation by 95% (Santen et al., 1978) . The site of production of the rest of the oestrone is unknown. These workers also found a subgroup of patients with much more rapid oestrone clearance but with no distinguishing clinical features. These metabolic differences in oestrone metabolism may be associated with the differences in hormone suppression by AG.
Body weight is another variable that affects aromatisation (Vermeulen & Verdonck, 1978) but non-responders with high oestrone levels were not heavier than the other patients, and few were over 70kg. The weight difference in responders compared with non-responders is in the opposite direction to that required to explain the higher oestrone levels. Similarly, years since the last _ _ _ _ _ _ _ menstrual cycle and age, which are both associated with increased aromatisation (Hemsell et al., 1974) did not account for the difference. The suppression of DHAS was more marked than that of oestrone, but there were no differences between responders and non-responders. Although each patient did not have samples taken at each time, it is shown in Figures 1 and 4 that the hormones were measured in the same patients and in the same blood samples. There is no difference in DHAS, yet there is in oestrone. The DHAS acts as an internal control.
Two other groups have compared smaller numbers of responders and non-responders to AG , Coombes et al., 1982 . Coombes et al. (1982) DHAS is suppressed by hydrocortisone, and not by AG alone (Harris et al., 1982c) . Thus, the high DHAS in non-responders in the series of may be reflection of the mode of administration of hydrocortisone. They gave 20mg in the evening and then 10mg in the morning and 10mg in the afternoon. We gave 20mg 12-hourly, which may be more effective in producing DHAS suppression at time of sample because of the larger morning dose. Their results with DHAS may therefore be a reflection of stress in progressing patients.
We are able to confirm Murray's (1981) observation that AG and hydrocortisone suppress testosterone levels. Santen et al. (1982) did not observe this but they only looked at 6 patients.
SHBG was measured as a marker of oestrogenicity of the peripheral hormone environment, since SHBG levels are raised by oestrogens and lowered by androgens (Anderson, 1974) . However, we found that SHBG rose in those patients who had not had tamoxifen in the 2 months before starting AG. SHBG is induced by other anticonvulsants (AG was originally marketed as an anticonvulsant) and may be a marker for liver enzyme induction (Victor et al., 1977) . Tamoxifen produces rises in SHBG (Sakai et al., 1978) and patients who had tamoxifen in the previous two months before starting AG had higher levels than the other patients. These levels fell on therapy with AG but this may just be a reflection on the long tissue half-life of tamoxifen. Thus SHBG levels did not differ between responders and non-responders and were not correlated with oestrone levels.
Prolactin levels before the start of treatment did not differ between responders and non-responders. The small significant rise in responders may be a response to increased thyrotrophin releasing hormone, since AG produces a rise in thyroidstimulating hormone (Santen et al., 1977b) . However, prolactin levels were found to be above 5OOmlUl-in 14 of the non-responders. A rise of prolactin in patients with progressive disease has been reported during therapy with dexamethasone in 6 patients (Borkowski et al., 1977) , but not during progression while on tamoxifen (Golder et al., 1976; Willis et al., 1977) .
The prolactin and oestrone results suggest subgroups of patients not responding to AG who may benefit from adding other endocrine therapy, i.e. tamoxifen for those with high oestrone, or bromocryptine for those with high prolactin. Although bromocryptine alone is ineffective (European Breast Cancer Group, 1972) , it has been shown to increase response rates to chemotherapy when given to patients with high prolactin (Nagel et al., 1982) . Combination endocrine therapy has not been shown to produce an increase in response rates (Tormey et al., 1976; Ward, 1977) , but if only a subgroup of patients benefit, then the numbers in most trials have been too small to detect even a 2-fold difference with 90% confidence. Many of the non-responders will be oestrogen receptor negative, but only 50% of oestrogen receptor positive patients respond to first line endocrine therapy or to endocrine therapy with AG (Lawrence et al., 1980) . Some of these oestrogen receptor-positive patients may fail to respond because of inadequate manipulation of the endocrine environment. This study shows that there are differences in the peripheral endocrine environment within one month of starting treatment in non-responders compared with responders. By using peripheral hormone assays, it is possible that "logical" endocrine therapy might be devised for individual patients. Such an approach will need to be studied in a prospective trial.
